Details of the Drug Reposition

General Information of This Drug (ID: DMPVRN9)

• Drug Name: Setmelanotide (DMPVRN9)
• Synonyms: RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Obesity	DIS47Y1K	5B81	Approved	[1]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bardet biedl syndrome	DISTBNZW	5A61.0	Phase 3	[2]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Prader-Willi syndrome	DISYWMLU	LD90.3	Phase 2	[3]

1 Preclinical Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Diabetic complication	DIS4S2FC	5A2Y	Preclinical	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] ClinicalTrials.gov (NCT03746522) Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alstrom Syndrome (AS) Patients With Moderate to Severe Obesity. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2011 Pipeline of Ipsen.